Showing 5111-5120 of 8588 results for "".
- New Blood Test Gets Leg Up On Advanced Melanomahttps://practicaldermatology.com/news/new-blood-test-gets-leg-up-on-advanced-melanoma/2458756/A blood test that monitors blood levels of DNA fragments from dead cancer cells may be better at tracking progression of metastatic melanoma than the current standard blood test. The standard test measures blood levels of the enzyme lactate dehydrogenase (LDH), which tend t
- Galderma Laboratories, L.P. Appoints Miles Harrison as Leader of U.S. and Canadahttps://practicaldermatology.com/news/galderma-laboratories-lp-appoints-miles-harrison-as-leader-of-us-and-canada/2458762/Galderma promoted Miles Harrison to President and General Manager of Galderma Laboratories, L.P. leading the US and Canada teams. Miles Harrison joined Galderma US in 2014 as the Vice President
- Anacor Submits NDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic Dermatitishttps://practicaldermatology.com/news/anacor-submits-nda-for-crisaborole-topical-ointment-2-for-the-treatment-of-mild-to-moderate-atopic-dermatitis/2458765/Anacor Pharmaceuticals, Inc. has submitted a New Drug Application (NDA) to the US FDA seeking approval of crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atopic d
- ASDS Honors Dr. Ian Maher for Outstanding Servicehttps://practicaldermatology.com/news/asds-honors-dr-ian-maher-for-outstanding-service/2458764/The American Society for Dermatologic Surgery (ASDS) last month presented Ian A. Maher, MD, of St. Louis with the ASDS Award for Outstanding Service. The award is given annually to one member who has volunteered his or her time for multiple Society projects or initiatives. In an effort to recogni
- Valeant Announces J. Michael Pearson Will Be On Medical Leave of Absencehttps://practicaldermatology.com/news/valeant-announces-j-michael-pearson-will-be-on-medical-leave-of-absence/2458770/Valeant Pharmaceuticals International, Inc. announced that chairman and chief executive officer J. Michael Pearson will be on a medical leave of absence, effective immediately. The company's board of directors has created an Office of the Chief Executive Officer, which will include Robert Cha
- MELA Sciences Changing Name to STRATA Skin Sciences to Reflect Broader Dermatology Commitmenthttps://practicaldermatology.com/news/mela-sciences-changing-name-to-strata-skin-sciences-to-reflect-broader-dermatology-commitment/2458771/MELA Sciences, Inc. will be changing its corporate name to STRATA Skin Sciences, Inc. effective Tuesday, January 5, 2016 and it will trade under the symbol “SSKN” on the Nasdaq Stock Market. Michael R. Stewart, President and Chief Executive Officer stated: “Our June 2015
- FDA Approves Expanded Indication for Merck's Keytruda for Treatment of Advanced Melanomahttps://practicaldermatology.com/news/fda-approves-expanded-indication-for-mercks-keytruda-for-treatment-of-advanced-melanoma/2458773/The FDA has approved an expanded indication for Merck’s Keytruda® (pembrolizumab), an anti-PD-1 (programmed death receptor-1) therapy, to include the first-line treatment of patients with unresectable or metastatic melanoma. This approval marks the second FDA-approved indicat
- One Third Of Surveyed Women Have Removed A Photo From Social Media To Hide Their Acnehttps://practicaldermatology.com/news/one-third-of-surveyed-women-have-removed-a-photo-from-social-media-to-hide-their-acne/2458775/According to a new U.S. survey conducted by TotalBeauty and ACZONE® (dapsone) Gel 5%, acne concerns affected the social media habits of women ages 20 to 39 (n=480) when it came to photos. Of the women surveyed, two in five (n=212) admitted to editing a photo to hide their acne, while one thir
- New Rosacea Research Findings Presented During SID Annual Meetinghttps://practicaldermatology.com/news/new-rosacea-research-findings-presented-during-sid-annual-meeting/2458777/Medical scientists reviewed research on the microbiome, genetics and pathophysiology of rosacea and presented results of new studies funded by the National Rosacea Society (NRS) during its research workshop at the Society for Investigative Dermatology annual meeting. “Research suppo
- Oculus Innovative Sciences Receives FDA Clearance for Microcyn-Based SebDerm Gelhttps://practicaldermatology.com/news/oculus-innovative-sciences-receives-fda-clearance-for-microcyn-based-sebderm-gel/2458780/Oculus Innovative Sciences, Inc. received a new 510(k) clearance from the FDA for the company’s new Microcyn®-based SebDerm Gel. As a prescription product, SebDerm Gel is intended to manage and relieve the burning, itching, erythema, scaling, and pain experienced with seborrh